tbuckley/cabot-search huggingface dataset:
Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications
Authors: Aurélie Plessier, Marina Esposito‐Farèse, Anna Baiges, Akash Shukla, Juan Carlos Garcia Pagan, Emmanuelle De Raucourt, Isabelle Ollivier‐Hourmand, Jean‐Paul Cervoni, Victor De Ledinghen, Zoubida Tazi, Jean‐Baptiste Nousbaum, René Bun, Christophe Bureau, Christine Silvain, Olivier Tournilhac, Mathieu Gerfaud‐Valentin, François Durand, Odile Goria, Luis Tellez, Agustin Albillos, Stefania Gioia, Oliviero Riggio, Andrea De Gottardi, Audrey Payance, Pierre‐Emmanuel Rautou, Louis Terriou, Aude Charbonnier, Laure Elkrief, Regis Peffault de la Tour, Dominique‐Charles Valla, Nathalie Gault, Flore Sicre de Fontbrune
Journal: American Journal of Hematology (2022)

A total of 2%-10% of patients with vascular liver disease (VLD) have paroxysmal nocturnal hemoglobinuria (PNH). Eculizumab reduces complement-mediated haemolytic activity in PNH. This study was aimed at assessing the impact of eculizumab on VLD outcome. Retrospective cohort of PNH patients, in Valdig registry, who had VLD diagnosed between 1997 and 2019 is considered. Eculizumab was the exposure of interest. Studied outcomes were death, venous thrombosis, bleeding, arterial ischemic event, infection, and liver-related complications. We compared survival and new thrombotic events from PNH/VLD cohort to Envie2 non-PNH cohort. Sixty-two patients (33 women), median age 35 years (28-48) and median follow-up VLD diagnosis 4.7 years (1.2-9.5), were included. Clone size was 80% (70-90), median hemoglobin concentration was 10.0 g/dl (8-11), and lactate dehydrogenase (LDH) was 736 IU (482-1744). Forty-two patients (68%) had eculizumab; median exposure time was 40.1 [9.3-72.6] months. Mortality was significantly lower in exposed versus nonexposed period: 2.6 versus 8.7 per 100 (PY), incidence rate ratio (IRR) was 0.29, 95% CI (0.1-0.9), p = .035. Thrombosis recurrence occurred less frequently during the exposure to eculizumab: 0.5 versus 2.8 per 100 PY, IRR 0.22 (0.07-0.64). Other secondary end points (i.e., bleeding, arterial ischemic lesions, infection, and liver complications) were less common during the exposure to eculizumab, although not reaching statistical significance. Six-year thrombosis-free survival was 70%, 95% CI [0.60-0.83] for PNH cohort and 83%, 95% CI [0.70-1.00] for non-PNH Envie 2 patients, (p < .001). In conclusion, patients with PNH and VLD are at higher risk of recurrent thrombosis than non-PNH patients. Eculizumab is significantly associated with a lower mortality and less thrombotic recurrence in patients with PNH and VLD.
Costs and benefits of communicating vigor
Authors: Cristina Becchio, Kiri Pullar, Stefano Panzeri
Journal: Behavioral and Brain Sciences (2021)

Why do we run toward people we love, but only walk toward others? One reason is to let them know we love them. In this commentary, we elaborate on how subjective utility information encoded in vigor is read out by others. We consider the potential implications for understanding and modeling the link between movements and decisions in social environments.
Current Therapeutic Research, New York
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patient Impressions and Outcomes After Clinic-Based Hidradenitis Suppurativa Surgery
Authors: Saranya Ravi, Jonathan A. Miles, Chelsea Steele, Mary Kate Christiansen, Christopher J. Sayed
Journal: JAMA Dermatology (2022)

<h3>Importance</h3> Surgical intervention is frequently needed to treat hidradenitis suppurativa (HS). Patient satisfaction is high based on previous studies, but reports of patient impressions of clinic-based operative experiences and postoperative recovery are limited. <h3>Objective</h3> To characterize patient impressions, outcomes, and recovery time after clinic-based surgical treatment of HS and examine patient characteristics associated with outcomes. <h3>Design, Setting, and Participants</h3> This retrospective cohort study included patients 12 years or older who underwent clinic-based surgical procedures for treatment of HS at a single subspecialty HS clinic at the University of North Carolina Department of Dermatology from April 2014 to December 2018. Data analysis was performed from January to September 2021. <h3>Exposures</h3> Clinic-based deroofing and excisional procedures performed as part of routine care. <h3>Main Outcomes and Measures</h3> The primary outcomes were patient-reported recurrence of HS at the site of surgery, patient satisfaction with the procedures and outcomes, and patient-reported pain and recovery associated with surgery obtained from electronic medical record review and patient questionnaires. <h3>Results</h3> Outcomes of 194 procedures for 78 patients (65 [83%] female; mean [SD] age, 35.1 [12.1] years) were analyzed. Self-reported rate of recurrence was 41% (79 procedures). Despite recurrence, most patients (148 procedures [76%]) were very satisfied with their surgical results. The median number of missed days of work or school was 2 (IQR, 1-7 days), and the median number of days until return to normal activity was 10 (IQR, 3-14 days). In addition, for 126 of the 194 procedures (65%), patients stated that pain during an HS flare was worse than pain during surgical recovery. <h3>Conclusions and Relevance</h3> In this cohort study, patients reported high rates of satisfaction with clinic-based HS surgery. Recovery was typically rapid, with most patients rating postsurgical pain as less severe than their HS pain.
Depressed plasma levels of extracellular matrix metalloproteinases 2 and 9 in patients with mild to moderate essential hypertension Emanuel V. Economou, Christos P. Pitsavos, Alexandra Zervoudaki, Konstantinos Tsioufis, Marina G. Toutouza, Konstantinos Kapetanios, Christodoulos I. Stefanadis, Pavlos K. Toutouzas. Dept. Cardiol, Univ. Athens, Hippokration Hospital, Athens, Greece
Journal: Journal of the American College of Cardiology (2001)
British Medical Journal, London
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
International Symposium on New Trends in Human Immunology and Cancer Immunotherapy
Journal: JNCI Journal of the National Cancer Institute (1979)

International Symposium on New Trends in Human Immunology and Cancer Immunotherapy JNCI: Journal of the National Cancer Institute, Volume 63, Issue 5, November 1979, Page 1285, https://doi.org/10.1093/jnci/63.5.1285 Published: 01 November 1979
Multivariate predictors of target lesion ravascularization in the randomized trial of PTCA versus rotablator for diffuse in-stent restenosis (ROSTER) Samin K. Sharma, Annapoorna S. Kini, Traci King, Felix D. Sterling, Paul Lee, Jonathan D. Marmur, David Reich. The Mount Sinai Medical Center, New York, NY
Journal: Journal of the American College of Cardiology (2001)
Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023—Updated results
Authors: L. A. Mina, M. A. Neubauer, R. H. Ansari, R. Govindan, L. H. Einhorn, W. Fisher, D. Bruetman, N. M. Chowhan, C. Johnson, N. H. Hanna
Journal: Journal of Clinical Oncology (2008)

7519 Background: Concurrent chemoradiation is standard treatment for pts with inoperable stage III NSCLC. We present updated results from a previously reported randomized phase III trial comparing EP/XRT with or without consolidation D (Hanna et al. ASCO 2007). Methods: Eligible pts had inoperable, stage IIIA/B NSCLC, PS 0–1, FEV-1 ≥ 1 L, and < 5% wt loss. Pts (n=243) received P 50 mg/m2 iv d 1,8,29,36 and E 50 mg/m2 iv d1–5, 29–33 concurrently with chest XRT to 5940 cGy. Non- progressing pts were randomized to D 75 mg/m2 iv every 21d for 3 cycles vs observation (O). The primary endpoint was to compare overall survival (OS) by Kaplan-Meier analysis. Accrual of 259 pts to randomize180 was planned to show a difference in median survival time (MST) of 25 vs 15 mos (5% 2-sided alpha, 80% power). Accrual reached 243 pts; however the DSMB recommended early termination, after analysis of 203 pts, based upon evidence of futility (p>0.7271). Results: Characteristics for all pts entered (n=243) were similar to pts evaluated by the DSMB (n=203): F: M 34%/66%; median age 63; PS 0/1 59.7%/40.3%; IIIA/B 41.2%/58.8%; FEV-1 >2 47.7%. Characteristics of all randomized pts (n=166; O arm: n=84; D arm: n=82) were similar to pts evaluated by the DSMB (n=147; O arm: n=74; D arm: n=73). Toxicities during EP/XRT and consolidation D were previously reported for the 203 pts evaluated by the DSMB. Similar rates of toxicities were observed for the entire cohort receiving EP/XRT and pts randomized to D. Updated survival rates for the previously reported pts evaluated by the DSMB as well as survival data for all pts entered and randomized are reported in Table 1. Conclusions: Our updated results confirm our prior conclusion that consolidation D does not improve survival following EP/XRT, is associated with significant toxicities and can no longer be considered as standard treatment for pts with inoperable stage III NSCLC. Patient population OS% at 3 years MST (mos) p-value * DSMB pts All (n=203) 30.2 21.72 NA O arm (n=74) 33.6 25.95 0.8484 D arm (n=73) 29.6 24.25 Entire cohort All (n=243) 29.9 21.52 NA O arm (n=84) 34.5 26.12 0.7499 D arm (n=82) 29.9 24.25 * Comparison of randomized arms only Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Eli Lilly Eli Lilly AstraZeneca Oncology, Aventis, Eli Lilly, Genentech™ BioOncology, Pfizer Oncology Merck
Randomized comparison between a low and a new high impedance true bipolar defibrillation lead Christina Unterberg, Jens Stevens, Dirk Vollmann, Holger Krieglstein, Dieter Zenker, for the worldwide 6944 Lead Study Group. Department of Cardiology, University Clinic, Goettingen Germany, Department of Cardiothoracic Surgery, University Clinic
Journal: Journal of the American College of Cardiology (2001)
Infarct on Brain Imaging, Subsequent Ischemic Stroke, and Clopidogrel-Aspirin Efficacy
Authors: Sara K. Rostanski, Alexandra Kvernland, Ava L. Liberman, Adam de Havenon, Nils Henninger, Brian Mac Grory, Anthony S. Kim, J. Donald Easton, S. Claiborne Johnston, Shadi Yaghi
Journal: JAMA Neurology (2022)

In the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial, acute treatment with clopidogrel-aspirin was associated with significantly reduced risk of recurrent stroke. There may be specific patient groups who are more likely to benefit from this treatment. To investigate whether the association of clopidogrel-aspirin with stroke recurrence in patients with minor stroke or high-risk transient ischemic attack (TIA) is modified by the presence of infarct on imaging attributed to the index event (index imaging) among patients enrolled in the POINT Trial. In the POINT randomized clinical trial, patients with high-risk TIA and minor ischemic stroke were enrolled at 269 sites in 10 countries in North America, Europe, Australia, and New Zealand from May 28, 2010, to December 19, 2017. In this post hoc analysis, patients were divided into 2 groups according to whether they had an acute infarct on index imaging. All POINT trial participants with information available on the presence or absence of acute infarct on index imaging were eligible for this study. Univariable Cox regression models evaluated associations between the presence of an infarct on index imaging and subsequent ischemic stroke and evaluated whether the presence of infarct on index imaging modified the association of clopidogrel-aspirin with subsequent ischemic stroke risk. Data were analyzed from July 2020 to May 2021. Presence or absence of acute infarct on index imaging. The primary outcome is whether the presence of infarct on index imaging modified the association of clopidogrel-aspirin with subsequent ischemic stroke risk. Of the 4881 patients enrolled in POINT, 4876 (99.9%) met the inclusion criteria (mean [SD] age, 65 [13] years; 2685 men [55.0%]). A total of 1793 patients (36.8%) had an acute infarct on index imaging. Infarct on index imaging was associated with ischemic stroke during follow-up (hazard ratio [HR], 3.68; 95% CI, 2.73-4.95; P < .001). Clopidogrel-aspirin vs aspirin alone was associated with decreased ischemic stroke risk in patients with an infarct on index imaging (HR, 0.56; 95% CI, 0.41-0.77; P < .001) compared with those without an infarct on index imaging (HR, 1.11; 95% CI, 0.74-1.65; P = .62), with a significant interaction association (P for interaction = .008). In this study, the presence of an acute infarct on index imaging was associated with increased risk of recurrent stroke and a more pronounced benefit from clopidogrel-aspirin. Future work should focus on validating these findings before targeting specific patient populations for acute clopidogrel-aspirin treatment.
Tissue Transplantation Conference
Journal: JNCI Journal of the National Cancer Institute (1953)

Tissue Transplantation Conference JNCI: Journal of the National Cancer Institute, Volume 14, Issue 3, December 1953, Page 667, https://doi.org/10.1093/jnci/14.3.667 Published: 01 December 1953 Article history Received: 14 August 1953 Published: 01 December 1953
Questions and Answers
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Coagulopathy associated with moxalactam
Authors: S. Lee
Journal: JAMA (1983)

<h3>To the Editor.—</h3> We read the article by R. L. Pakter et al (1982;248:1100) about the coagulopathy associated with the use of moxalactam disodium. We have seen three cases recently of qualitative platelet defects associated with the use of moxalactam that we would like to report. <h3>Report of Cases.—Case 1.—</h3> An 86-year-old man was admitted to the hospital with cerebrovascular accident. He needed gastrostomy tube insertion. Results of Quick's prothrombin time, partial thromboplastin time (PTT), and bleeding time tests were normal preoperatively. Aspiration pneumonias developed and therapy with moxalactam was started. Subsequent to this, the PTT prolonged to 64 s (normal, &lt;40 s), and the Simplate bleeding time was more than 30 minutes (normal, less than seven minutes). Platelet aggregometry showed no reaction with collagen and disaggregation with high-dose adenosine diphosphate. Ristocetin and epinephrine levels were normal. Moxalactam administration was discontinued, and the patient was treated with vitamin
THREE-DIMENSIONAL AORTIC ANNULAR ASSESSMENT BY MULTIDETECTOR COMPUTED TOMOGRAPHY PREDICTS MODERATE OR SEVERE PARAVALVULAR REGURGITATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT : A MULTICENTER RETROSPECTIVE ANALYSIS
Authors: Alex Willson, John Webb, Troy LaBounty, Stephan Achenbach, Robert Moss, Miriam Wheeler, Christopher Thompson, James Min, Ronen Gurvitch, Bjarne Norgard, Stefan Toggweiler, Ronald K. Binder, Cameron Hague, Melanie Freeman, Steen H. Poulter, Rohen Poulter, David Wood, Leipsic Jonathon
Journal: Journal of the American College of Cardiology (2012)
Medicolegal
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AMA-RPS Chooses Chairperson-Elect
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical and angiographic results of 1-year follow-up after coronary artery stenting in unstable angina Julinda Mehilli, Adnan Kastrati, Josef Dirschinger, J�rgen Pache, Helmut Sch�hlen, Franz-Josef Neumann, Albert Sch�mig. Deutsches Herzzentrum, Munich, Germany, 1. Med. Klinik rechts der Isar der TU M�nchen, Munich, Germany
Journal: Journal of the American College of Cardiology (2001)
Commentaire de travail de Alvarez Herrero L et al., pp. 98
Journal: Endoscopy (2014)

See also:Narrow band imaging does not reliably predict residual intestinal metaplasia after radiofrequency ablation at the neo-squamo columnar junctionEndoscopy 2014; 46(02): 98-104DOI: 10.1055/s-0033-1344986
Using machine learning to uncover heterogeneity of beta blocker response in heart failure
Authors: Geoffrey H. Tison
Journal: Cell Reports Medicine (2022)

A recent study by Karwath et al.1Karwath A. Bunting K.V. Gill S.K. Tica O. Pendleton S. Aziz F. Barsky A.D. Chernbumroong S. Duan J. Mobley A.R. et al.card AIc group and the Beta-blockers in Heart Failure Collaborative GroupRedefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis.Lancet. 2021; 398: 1427-1435Abstract Full Text Full Text PDF Scopus (7) Google Scholar in The Lancet applied machine learning-based cluster analysis to pooled data from nine double-blind, randomized controlled trials of beta blockers, identifying subgroups of efficacy in patients with sinus rhythm and atrial fibrillation.
Social Epidemiology: Past, Present, and Future
Authors: Ana V. Diez Roux
Journal: Annual Review of Public Health (2022)

In a context where epidemiologic research has been heavily influenced by a biomedical and individualistic approach, the naming of “social epidemiology” allowed explicit emphasis on the social production of disease as a powerful explanatory paradigm and as critically important for interventions to improve population health. This review briefly highlights key substantive areas of focus in social epidemiology over the past 30 years, reflects on major advances and insights, and identifies challenges and possible future directions. Future opportunities for social epidemiology include grounding research in theoretically based and systemic conceptual models of the fundamental social drivers of health; implementing a scientifically rigorous yet realistic approach to drawing conclusions about social causes; using complementary methods to generate valid explanations and identify effective actions; leveraging the power of harmonization, replication, and big data; extending interdisciplinarity and diversity; advancing emerging critical approaches to understanding the health impacts of systemic racism and its policy implications; going global; and embracing a broad approach to generating socially useful research.